focus -WSS

focus

author：hotspot 2025-09-29 22:50:04 - browse：84986

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Devoted Health’s losses in Medicare Advantage persist

leisure time

WSS

Telehealth startups are trying to fill the menopause care vacuum

AstraZeneca stays mum on Medicare drug pricing negotiations

Delta passengers in Vegas fall sick while waiting on flight in triple

Scientists grapple with ethics of stem cell research

US jobless claims fall again as labor market continues to flash strength

Padmanee Sharma of MD Anderson at center of lawsuit over credit

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Malaria cases in Florida and Texas: Here’s what you need to know

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Virginia high school admissions case could be legal follow

340B reform proposal comes out of Senate working group

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Unique patient identifier: Experts argue the benefits, pitfalls

Jerome Adams on the need for new antivirals for Covid

Unique patient identifier: Experts argue the benefits, pitfalls

knowledge

Extensive review finds private equity owners jack up cost of care

AI gets buy

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Sanders wants to replace patents with prizes for drug inventions

Mystery swirls around US soldier who entered North Korea days ago, officials say

US jobless claims fall again as labor market continues to flash strength

entertainment

leisure time

explore

entertainment